| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; loading ...; fig s1c
| Morrissey M, Byrne R, Nulty C, McCabe N, Lynam Lennon N, Butler C, et al. The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation. BMC Cancer. 2020;20:566 pubmed publisher |
- flow cytometry; human; loading ...; fig 4e
| Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher |
- flow cytometry; human; loading ...; fig 5b, 5d, e4f
| Mendoza J, Escalante N, Jude K, Sotolongo Bellon J, Su L, Horton T, et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567:56-60 pubmed publisher |
- flow cytometry; human; loading ...; fig s5a
| Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig s1a
| Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher |
| Nishi W, Wakamatsu E, Machiyama H, Matsushima R, Saito K, Yoshida Y, et al. Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters. Nat Commun. 2023;14:3157 pubmed publisher |
| Baleeiro R, Bouwens C, Liu P, DI Gioia C, Dunmall L, Nagano A, et al. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Oncoimmunology. 2022;11:2080329 pubmed publisher |
| Yang Z, Wang Y, Liu S, Deng W, Lomeli S, Moriceau G, et al. Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer Discov. 2022;12:1942-1959 pubmed publisher |
| Zhang Z, Yang A, Chaurasiya S, Park A, Lu J, Kim S, et al. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2022;29:722-733 pubmed publisher |
| Meng Q, Xie S, Gray G, Dezfulian M, Li W, Huang L, et al. Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. J Immunother Cancer. 2021;9: pubmed publisher |
| Curnock A, Bossi G, Kumaran J, Bawden L, Figueiredo R, Tawar R, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021;6: pubmed publisher |
| Sekine T, Perez Potti A, Rivera Ballesteros O, Stralin K, Gorin J, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158-168.e14 pubmed publisher |
| Wang H, Fu C, Du J, Wang H, He R, Yin X, et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res. 2020;39:29 pubmed publisher |
| RIEDER S, Wang J, White N, Qadri A, Ménard C, Stephens G, et al. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling. Cell Mol Immunol. 2021;18:1503-1511 pubmed publisher |
| Mancuso R, Casper J, Schmidt A, Krahenbuhl S, Weitz Schmidt G. Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality. Br J Pharmacol. 2020;177:2696-2711 pubmed publisher |
| Grandclaudon M, Perrot Dockès M, Trichot C, Karpf L, Abouzid O, Chauvin C, et al. A Quantitative Multivariate Model of Human Dendritic Cell-T Helper Cell Communication. Cell. 2019;179:432-447.e21 pubmed publisher |
| Wang B, Zuo J, Kang W, Wei Q, Li J, Wang C, et al. Generation of Hutat2:Fc Knockin Primary Human Monocytes Using CRISPR/Cas9. Mol Ther Nucleic Acids. 2018;11:130-141 pubmed publisher |
| Chaganty B, Qiu S, Gest A, Lu Y, Ivan C, Calin G, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion. Cancer Lett. 2018;430:47-56 pubmed publisher |
| Wilson J, Zhao Y, Singer M, Spencer J, Shankar Hari M. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. Crit Care. 2018;22:95 pubmed publisher |
| Yamada S, Itai S, Kaneko M, Kato Y. Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. Biochem Biophys Rep. 2018;13:123-128 pubmed publisher |
| Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher |
| Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker J, et al. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J Immunol. 2017;199:604-612 pubmed publisher |
| Watanabe R, Shirai T, Namkoong H, Zhang H, Berry G, Wallis B, et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725-2738 pubmed publisher |
| Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher |
